Biomedicines (Aug 2024)

Radiotherapy and Systemic Treatment for Leptomeningeal Disease

  • Kelsey M. Frechette,
  • William G. Breen,
  • Paul D. Brown,
  • Ugur T. Sener,
  • Lauren M. Webb,
  • David M. Routman,
  • Nadia N. Laack,
  • Anita Mahajan,
  • Eric J. Lehrer

DOI
https://doi.org/10.3390/biomedicines12081792
Journal volume & issue
Vol. 12, no. 8
p. 1792

Abstract

Read online

Leptomeningeal disease (LMD) is a devastating sequelae of metastatic spread that affects approximately 5% of cancer patients. The incidence of LMD is increasing due to advancements in systemic therapy and enhanced detection methods. The purpose of this review is to provide a detailed overview of the evidence in the detection, prognostication, and treatment of LMD. A comprehensive literature search of PUBMED was conducted to identify articles reporting on LMD including existing data and ongoing clinical trials. We found a wide array of treatment options available for LMD including chemotherapy, targeted agents, and immunotherapy as well as several choices for radiotherapy including whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and craniospinal irradiation (CSI). Despite treatment, the prognosis for patients with LMD is dismal, typically 2–4 months on average. Novel therapies and combination approaches are actively under investigation with the aim of improving outcomes and quality of life for patients with LMD. Recent prospective data on the use of proton CSI for patients with LMD have demonstrated its potential survival benefit with follow-up investigations underway. There is a need for validated metrics to predict prognosis and improve patient selection for patients with LMD in order to optimize treatment approaches.

Keywords